← Back to Search

Kinase Inhibitor

Edecesertib for Cutaneous Lupus Erythematosus (LYNX Trial)

Phase 1
Waitlist Available
Research Sponsored by Gilead Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first dose date up to 4 weeks plus 28 days
Awards & highlights

LYNX Trial Summary

This study is evaluating whether a drug called GS-5718 is safe and well tolerated in people with cutaneous lupus erythematosus.

Eligible Conditions
  • Cutaneous Lupus Erythematosus

LYNX Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first dose date up to 4 weeks plus 28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and first dose date up to 4 weeks plus 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants Who Experienced Treatment-emergent Adverse Events
Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities
Secondary outcome measures
Pharmacokinetic (PK) Parameter: AUCtau of Edecesertib
Pharmacokinetic (PK) Parameter: Cmax of Edecesertib

LYNX Trial Design

2Treatment groups
Experimental Treatment
Group I: PlaceboExperimental Treatment2 Interventions
Participants continuing their standard of care therapy will receive placebo to match edecesertib orally once daily for up to 4 weeks.
Group II: EdecesertibExperimental Treatment2 Interventions
Participants continuing their standard of care therapy will receive edecesertib at a dose of 115 mg orally once daily for up to 4 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Standard of Care
2017
Completed Phase 4
~4420
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

Gilead SciencesLead Sponsor
1,084 Previous Clinical Trials
848,259 Total Patients Enrolled
Gilead Study DirectorStudy DirectorGilead Sciences
343 Previous Clinical Trials
186,690 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
2021. "Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04809623.
~1 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top